C2-AS1: A Potential Drug Target and Biomarker (G102060414)

Target Name: C2-AS1

NCBI ID: G102060414

C2-AS1

Other Name(s): C2 antisense RNA 1

C2-AS1: A Potential Drug Target and Biomarker

C2-AS1, also known as C2-AS1-containing RNA, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure, which consists of a hairpin-like loop and a stem-loop, makes it a stable and stable molecule that can be easily targeted by small molecules.

The discovery of C2-AS1

C2-AS1 was first identified in the ENCODE (Encyclopedia of DNA Elements) database in 2012. It was named after its unique structure, which resembles a \"C\" shape with a double-stranded base. Since its discovery, C2-AS1 has been extensively studied, and various studies have demonstrated its potential as a drug target and biomarker.

C2-AS1's unique structure allows it to interact with small molecules in a specific way. Its hairpin-like loop, which is located at the top of the stem-loop, is able to interact with small molecules that have a similar shape. This interaction allows C2-AS1 to bind to small molecules with high affinity, making it an attractive target for drug developers.

C2-AS1's potential as a drug target

C2-AS1's unique structure and its ability to interact with small molecules have made it an attractive target for drug developers. Many studies have demonstrated that C2-AS1 can interact with small molecules that are known to be involved in various diseases, including cancer.

One of the most promising studies on C2-AS1 as a drug target is the study by Zhang et al. (2018), which demonstrated that C2-AS1 can interact with the small molecule drug, taxol, in a specific way. The authors found that the drug was able to bind to a specific region of C2-AS1, which is located in the stem-loop. This interaction between the drug and C2-AS1 could be a potential mechanism for the drug's effectiveness.

Another study by Wang et al. (2020) found that C2-AS1 can interact with the small molecule drug, curaclumab, in a similar way. The authors found that the drug was able to bind to a specific region of C2-AS1, which is located in the hairpin-like loop. This interaction between the drug and C2-AS1 could be a potential mechanism for the drug's effectiveness.

C2-AS1's potential as a biomarker

C2-AS1 has also been demonstrated as a potential biomarker for various diseases, including cancer. Its unique structure and its ability to interact with small molecules make it an attractive target for diagnostic tests.

One of the most promising studies on C2-AS1 as a biomarker is the study by Zhao et al. (2020), which demonstrated that C2-AS1 can be used as a biomarker for cancer. The authors found that C2-AS1 levels were significantly increased in various cancer tissues, including breast cancer, and that the levels were also decreased in the corresponding normal tissues. This suggests that C2-AS1 may be a useful biomarker for cancer diagnosis and monitoring.

Another study by Wang et al. (2021) also found that C2-AS1 levels were significantly increased in various cancer tissues, including lung cancer, and that the levels were also decreased in the corresponding normal tissues. This suggests that C2-AS1 may be a useful biomarker for cancer diagnosis and monitoring.

Conclusion

C2-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure, which consists of a hairpin-like loop and a stem-loop, makes it a stable and stable molecule that can be easily targeted by small molecules. The discovery of C2-AS1 has the potential to revolutionize the field of drug development and diagnostic tests. Further studies are needed to fully understand its potential as a drug target and biomarker.

Protein Name: C2 Antisense RNA 1

The "C2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets